The dynamics of acute kidney injury market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of the emerging therapies during the forecast period.
LAS VEGAS, June 21, 2022 /PRNewswire/ -- DelveInsight's Acute Kidney Injury Market Insights report includes a comprehensive understanding of current treatment practices, Acute Kidney Injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Acute Kidney Injury Market Report
- As per DelveInsight analysis, the Acute Kidney Injury market size in the 7MM was approximately USD 5.4 billionin 2020.
- As per DelveInsight analysis, the total Acute Kidney Injury incident cases in the 7MM were approximately 10.9 million in 2020.
- The United States contributed to the largest incident-patient share (mortality adjusted), acquiring ~ 34.09% of the 7MM in 2020
- Rising incidence of AKI will provide a larger window of opportunity for new treatment and prevention options
- The pipeline of AKI is quite robust with diverse products strengthening targeting prophylaxis of AKI in several complications such as Sepsis and post-cardiac-surgery mainlyLeading acute kidney injury companies such as Cerenis Therapeutics, Alloksys, Vifor Pharma, Exponential Biotherapies, Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, Nephraegis Therapeutics, Vasomune, Unicycive, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, ABIONYX, and others are developing novel drug candidates to improve the Acute Kidney Injury treatment landscape.
- The Acute Kidney Injury therapies in the pipeline include bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others.
- The key driver for the surge in acute kidney injury market size is the rise in the number of incident cases of acute kidney injury.
Discover more about therapies set to grab major acute kidney injury market share @ Acute Kidney Injury Market Landscape
Acute Kidney Injury Overview
Acute kidney injury (AKI), also known as acute renal failure (ARF), is a disorder that causes progressive azotemia with or without oliguria over a period of hours or days. Acute kidney injury is defined as a sudden loss of renal function, clinically expressed as an acute reversible surge in nitrogen waste products as measured by blood urea nitrogen and serum creatinine levels over hours to weeks. Acute kidney injury causes an abrupt loss in renal function, which results in waste product retention, electrolyte abnormalities, and changes in volume status. Acute kidney injury is classified into prerenal, postrenal, and intrinsic renal.
Many people with acute kidney injury are asymptomatic, while others experience generalized non-specific acute kidney injury symptoms such as nausea, vomiting, weakness, dizziness, lower back pain, passing less urine than usual, unexplained loss of appetite, feeling sick or vomiting, shortness of breath, and swelling of the legs or other body parts. An increase in serum creatinine and a reduction in urine output are commonly used for acute kidney injury diagnosis.
Acute Kidney Injury Epidemiology Segmentation
As per DelveInsight, there were approx 10.9 million acute kidney injury incident cases in the 7MM in 2020.
Among the EU5 countries, Germany had the highest acute kidney injury incident population in 2020.
The Acute Kidney Injury market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into
- Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients
- Mortality Adjusted Incident Population of AKI in Hospitalized Patients
- Stage-specific Incident Population of AKI
- Age-specific Incident Population of AKI
Download the report to understand which factors are driving acute kidney injury epidemiology trends @ Acute Kidney Injury Epidemiological Insights
Acute Kidney Injury Treatment Market
For the past several years; it has been observed that the current acute kidney injury treatment is primarily supportive in character, with no therapeutic approaches demonstrating benefit in treating the condition. Off-label acute kidney injury medications used to treat AKI include ACE inhibitors, angiotensin II-receptor blockers (ARBs), diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and renal replacement therapy (RRT). Monitoring urine output and, at first, serum creatinine levels (SCr) numerous times each day is a cornerstone of the therapy for all patients with acute kidney injury. It is also indicated to correct electrolyte imbalances, quit or adjust nephrotoxic medicines, and dose-adjust pharmaceuticals with renal elimination.
To know more about Acute Kidney Injury treatment, visit @ Acute Kidney Injury Guidelines
Acute Kidney Injury Pipeline Therapies and Key Companies
- bRESCAP: Alloksys
- ANG-3777 (BB3): Angion Biomedica/ Vifor Pharma
- EA-230: Exponential Biotherapies
- Ilofotase alfa: AM Pharma
- ASP1128: Astellas Pharma
- Ruconest (Conestat alfa): Pharming Technologies
Learn more about the acute kidney injury medications @ Drugs for Acute Kidney Injury
Acute Kidney Injury Market Dynamics
Treatment-related adverse effects are quite rare, resulting in successful acute kidney injury treatment choices. Moreover, patients have easy access to reimbursements since their ailment necessitates long-term management, such as dialysis. In addition, several government activities are being undertaken by adopting various programs concerning acute kidney injury, which is expected to improve the global AKI prospect and thus bolster the actue kidney injury market.
Furthermore, several biomarkers, including NGAL, Cystatin-C, and others, are being investigated for use in acute kidney injury diagnosis. The validation of these new biomarkers could provide new methods for detecting the start and severity of kidney injury. Future research in the acute kidney injury market is underway with the goal of better understanding of the underlying processes and, as a result, improve outcomes for AKI patients.
Moreover, a robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the acute kidney injury market. Additionally, the acute kidney injury pipeline is also expected to change the current dynamics of the acute kidney injury market, which presently comprises biologics and molecules with new mechanisms of action like ANG-3777 (BB3), ASP1128, Ilofotase alfa, Ruconest (Conestat alfa), bRESCAP, EA230, and others.
However, there are several barriers to the acute kidney injury market growth. One such factor is the lack of awareness. If the patients have cardiac issues, the situation becomes even more complex. Moreover, long-term health repercussions, as well as longer hospital stays and high health-care expenses, highlight AKI's enormous societal impact. In addition, several risk factors, such as diabetes and heart failure, have substantial implications for patients' quality of life, making it challenging to develop promising future interventions and thus hindering the acute kidney injury market growth.
Scope of the Acute Kidney Injury Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Acute Kidney Injury Companies: Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, Nephraegis Therapeutics, Vasomune, Unicycive, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, ABIONYX, and others
- KeyAcute Kidney Injury Therapies: bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others
- Therapeutic Assessment: Acute kidney injury current marketed and emerging therapies
- Acute Kidney InjuryMarket Dynamics: Acute kidney injury market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Acute Kidney Injury Market Access and Reimbursement
Discover more about acute kidney injury drugs in development @ Acute Kidney Injury Clinical Trials
Table of Contents
1 | Key Insights |
2 | Report Introduction |
3 | Acute Kidney Injury (AKI) Market Overview at a Glance |
3.1 | Market Share by Therapies (%) Distribution of Acute Kidney Injury (AKI) in 2019 |
3.2 | Market Share by Therapies (%) Distribution of Acute Kidney Injury (AKI) in 2032 |
4 | Executive Summary of Acute Kidney Injury (AKI) |
5 | Key Events |
6 | SWOT Analysis |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Symptoms |
7.3 | Types of Acute Kidney Injury (AKI) |
7.4 | Stages Classification |
7.5 | Risk Factors |
7.6 | Etiology |
7.7 | Pathophysiology |
7.8 | Biomarkers |
7.9 | Diagnosis |
7.9.1 | RIFLE Criteria |
7.9.2 | AKIN Criteria |
7.9.3 | KDIGO criteria |
8 | Treatment and Prevention |
8.1 | Acute Renal Failure or Acute Kidney Injury: United States based Treatment Guidelines |
8.2 | European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury |
8.3 | The Japanese Clinical Practice Guideline for acute kidney injury (2016) |
8.4 | NICE Guidelines on AKI: Prevention, Detection, and Management (2019) |
8.4.1 | Assessing Risk of AKI |
8.4.2 | Preventing AKI |
8.4.3 | Detecting AKI |
8.4.4 | Identifying the Cause of AKI |
8.4.5 | Managing AKI |
8.4.6 | Information and Support for Patients and Carers |
9 | Epidemiology and Patient Population |
9.1 | Key Findings |
9.2 | Epidemiology Methodology |
9.3 | Total Incidence of Acute Kidney Injury (AKI) in Hospitalized Patients in the 7MM |
9.4 | Total Mortality Adjusted Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in the 7MM |
9.5 | Epidemiology of Acute Kidney Injury (AKI) |
9.5.1 | United States |
9.5.2 | Europe |
9.5.3 | Japan |
9.6 | The United States |
9.6.1 | Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in the United States |
9.6.2 | Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the United States |
9.6.3 | Stage-specific Incident Population of AKI in the United States |
9.6.4 | Age-specific Incident Population of AKI in the United States |
9.7 | EU5 |
9.7.1 | Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in EU5 |
9.7.2 | Mortality Adjusted Incident Population of AKI in Hospitalized Patients in EU5 |
9.7.3 | Stage-specific Incident Population of AKI in EU5 |
9.7.4 | Age-specific Incident Population of AKI in EU5 |
9.8 | Japan |
9.8.1 | Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in Japan |
9.8.2 | Mortality Adjusted Incidence of AKI in Hospitalized Patients in Japan |
9.8.3 | Stage-specific Incident Population of AKI in Japan |
9.8.4 | Age-specific Incidence of AKI in Japan |
10 | Organizations contributing towards Acute Kidney Injury (AKI) |
11 | Patient Journey |
12 | Emerging Therapies |
12.1 | Key Cross |
12.2 | bRESCAP: Alloksys |
12.2.1 | Product Description |
12.2.2 | Clinical Development |
12.2.2.1 | Clinical Trials Information |
12.3 | ANG-3777 (BB3): Angion Biomedica |
12.3.1 | Product Description |
12.3.2 | Clinical Development |
12.3.2.1 | Clinical Trials Information |
12.3.3 | Safety and Efficacy |
12.4 | Teprasiran (QPI-1002): Quark Pharmaceuticals |
12.4.1 | Product Description |
12.4.2 | Clinical Development |
12.4.2.1 | Clinical Trials Information |
12.4.3 | Safety and Efficacy |
12.5 | recAP: AM Pharma |
12.5.1 | Product Description |
12.5.2 | Clinical Development |
12.5.2.1 | Clinical Trials Information |
12.5.3 | Safety and Efficacy |
12.6 | ASP1128: Astellas Pharma |
12.6.1 | Product Description |
12.6.2 | Clinical Development |
12.6.2.1 | Clinical Trials Information |
12.7 | Ruconest (Conestat alfa): Pharming Technologies |
12.7.1 | Product Description |
12.7.2 | Clinical Development |
12.7.2.1 | Clinical Trials Information |
12.7.3 | Safety and Efficacy |
12.8 | EA-230: Exponential Biotherapies |
12.8.1 | Product Description |
12.8.2 | Clinical Development |
12.8.2.1 | Clinical Trials Information |
12.8.3 | Safety and Efficacy |
12.9 | Reltecimod: Atox Bio |
12.9.1 | Product Description |
12.9.2 | Clinical Development |
12.9.2.1 | Clinical Trials Information |
13 | Potential of Current Therapies and Emerging Therapies |
14 | Acute Kidney Injury (AKI): Seven Major Market Analysis |
14.1 | Key Findings |
14.2 | Market Methodology |
14.3 | Total Market Size of Acute Kidney Injury (AKI) in the 7MM |
14.4 | Total Market Size of Acute Kidney Injury (AKI) by Therapies in the 7MM |
14.5 | Market Outlook |
14.6 | Key Market Forecast Assumptions |
14.7 | United States Market Size |
14.7.1 | Total Market Size of Acute Kidney Injury (AKI) in the United States |
14.7.2 | Market Size of Acute Kidney Injury (AKI) by Therapies in the United States |
14.8 | EU-5 Market Size |
14.8.1 | Total Market size of Acute Kidney Injury (AKI) in Europe |
14.8.2 | Market Size of Acute Kidney Injury (AKI) by Therapies in Europe |
14.9 | Japan |
14.9.1 | Total Market size of Acute Kidney Injury (AKI) in Japan |
14.9.2 | Market Size of Acute Kidney Injury (AKI) by Therapies in Japan |
15 | KOL Views |
16 | Market Drivers |
17 | Market Barriers |
18 | Unmet Needs |
19 | Reimbursement and Market Access |
19.1 | Centers of Medicare and Medicaid Services (US) |
19.2 | American Kidney Fund (AKF) |
19.3 | Reimbursement and Cost of Acute Kidney Injury in Europe |
19.3.1 | United Kingdom (England) |
19.3.2 | France |
19.3.3 | Germany |
19.3.4 | Italy |
20 | Appendix |
20.1 | Bibliography |
20.2 | Report Methodology |
21 | DelveInsight Capabilities |
22 | Disclaimer |
23 | About DelveInsight |
Get in touch with our Business executive @ Healthcare Due Diligence Services
Related Reports
Acute Kidney Injury Pipeline
Acute Kidney Injury Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key acute kidney injury companies including Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, among others.
Acute Kidney Injury Epidemiology Forecast
Acute Kidney Injury Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute kidney injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Kidney Disease Pipeline
Chronic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key chronic kidney disease companies, including Bayer, AstraZeneca, Celgene, Ipsen, among others.
Anemia in Chronic Kidney Disease Pipeline
Anemia in Chronic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in chronic kidney disease companies, including Pieris Pharmaceuticals, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, among others.
Diabetic Kidney Disease Pipeline
Diabetic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key diabetic kidney disease companies, including Gilead Sciences, Kyowa Kirin, Bayer, among others.
Polycystic Kidney Disease Pipeline
Polycystic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in polycystic kidney disease companies, including Abbott, Reata Pharmaceuticals, XORTX Therapeutics, Sanofi Genzyme, among others.
Kidney Transplant Rejection Pipeline
Kidney Transplant Rejection Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in kidney transplant rejection companies, including Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Novartis, among others.
Other Trending Reports
Pediatric Growth Hormone Deficiency Market | Non-Cystic Fibrosis Bronchiectasis Market | X-Linked Retinitis Pigmentosa Market | Otitis Media Market | Central Retinal Vein Occlusion Market | Frontotemporal Dementia Market | Follicular Lymphoma Market | Diabetes Market | Blastic Plasmacytoid Dendritic Cell Neoplasm Market | Bevacizumab Biosimilars Insight | Bacterial Conjunctivitis Market | FENEBRUTINIB Market | Peripherally Inserted Central Catheter Devices Market | Cardiac Biomarkers Testing Devices Market
Related Healthcare Blogs
Acute Kidney Injury Market Outlook
Acute Kidney Injury Treatment Market
IgA Nephropathy Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
